



# Circulating adiponectin and cardiovascular mortality in patients with type 2 diabetes mellitus: evidence of sexual dimorphism

## Citation

Menzaghi, C., M. Xu, L. Salvemini, C. De Bonis, G. Palladino, T. Huang, M. Copetti, et al. 2014. "Circulating adiponectin and cardiovascular mortality in patients with type 2 diabetes mellitus: evidence of sexual dimorphism." *Cardiovascular Diabetology* 13 (1): 130. doi:10.1186/s12933-014-0130-y. <http://dx.doi.org/10.1186/s12933-014-0130-y>.

## Published Version

doi:10.1186/s12933-014-0130-y

## Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:12987255>

## Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

## Share Your Story

The Harvard community has made this article openly available.  
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

ORIGINAL INVESTIGATION

Open Access

# Circulating adiponectin and cardiovascular mortality in patients with type 2 diabetes mellitus: evidence of sexual dimorphism

Claudia Menzaghi<sup>1\*†</sup>, Min Xu<sup>2,3†</sup>, Lucia Salvemini<sup>1</sup>, Concetta De Bonis<sup>1</sup>, Giuseppe Palladino<sup>1</sup>, Tao Huang<sup>2</sup>, Massimiliano Copetti<sup>4</sup>, Yan Zheng<sup>2</sup>, Yanping Li<sup>2</sup>, Grazia Fini<sup>1</sup>, Frank B Hu<sup>2,5</sup>, Simonetta Bacci<sup>6</sup>, Lu Qi<sup>2,5</sup> and Vincenzo Trischitta<sup>1,7\*</sup>

## Abstract

**Background:** The pathogenesis of cardiovascular (CV) mortality, whose rate is increased in type 2 diabetes, is poorly understood.

While high serum adiponectin is associated with increased CV mortality in the general population, no data are available in type 2 diabetes.

We here investigated whether this counterintuitive association was observable also in diabetic patients and whether it was sex-specific.

**Methods:** Three prospective cohorts were analyzed: 1) Gargano Heart Study (GHS; 359 patients, 58 events/1,934 person-years; py); 2) Health Professional Follow-up Study (HPFS; 833 men, 146 events/10,024 py); 3) Nurses' Health Study (NHS; 902 women, 144 events/15,074 py).

**Results:** In GHS serum adiponectin predicted CV mortality in men (hazard ratio, HR, and 95% CI per standard deviation, SD, increment = 1.54, 1.19-2.01), but not women (HR = 0.98, 0.48-2.01). Circulating adiponectin predicted CV mortality in men from HPFS (HR = 1.44, 1.21-1.72), but not in women from NHS (HR = 1.08, 0.86-1.35), used as replication samples. In a pooled analysis, HRs were 1.47 (1.27-1.70) in 1,075 men and 1.07 (0.86-1.33) in 1,019 women (p for HRs heterogeneity across sexes = 0.018).

**Conclusions:** This is the first report showing that high circulating adiponectin predicts increased CV mortality in men, but not in women with type 2 diabetes. Further studies are necessary to unravel the mechanisms through which adiponectin influences CV mortality in a sex-specific manner.

**Keywords:** Adipokines, Prospective studies, Paradoxical effect, Sex-linked genes

The rate of cardiovascular (CV) mortality is doubled in patients with type 2 diabetes as compared to that of non diabetic individuals [1] and definitively remains their first cause of death [1]. The exact pathogenic mechanisms, underlying such increased risk are poorly understood.

Adiponectin, a 244-amino acid protein secreted by adipocytes has insulin-sensitizing, anti-inflammatory, and

endothelial protective effects [2,3] and exerts a protective role in myocardial infarction (MI) [4,5] and coronary heart disease (CHD) [6-8]. Thus, it is surprising that, high adiponectin levels predict increased risk of heart failure (HF) [9,10] as well as CV mortality in the general population and in selected clinical settings [11-21]. A similar unexpected paradoxical association with the risk of CV mortality has been also described in patients with type 1 diabetes [22] and in kidney transplant recipients [23]. Whether this is the case also among patients with type 2 diabetes has never been addressed.

Interestingly, it has been recently reported that in humans there is a sex-specific effect of serum adiponectin

\* Correspondence:

c.menzaghi@operapadrepio.it; vincenzo.trischitta@uniroma1.it

†Equal contributors

<sup>1</sup>Research Unit of Diabetes and Endocrine Diseases IRCCS Casa Sollievo della Sofferenza, Viale Padre Pio, 71013 San Giovanni Rotondo, Italy

<sup>7</sup>Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy

Full list of author information is available at the end of the article

in the development of type 2 diabetes [24] and in the progression of chronic kidney disease [25]; also data in mice with genetically induced endothelial dysfunction in which adiponectin exerts its beneficial effect on heart function and remodeling in female but not male are compatible with a sexual dimorphism [26]. While some studies have not reported a sex-specific effect of adiponectin on CHD [27] and cardiovascular events [28], no data are so far available on CV mortality.

In order to investigate whether serum adiponectin plays a role in CV mortality in type 2 diabetes in a sex-specific manner, we analyzed data from over 2,000 diabetic patients of European origin from three independent established cohorts from Italy and the US followed over time for several years.

## Material and methods

### Study populations

#### *GHS-prospective design*

This study comprises 368 patients with type 2 diabetes (ADA 2003 criteria) and coronary artery disease who were consecutively recruited at the Endocrine Unit of IRCCS “Casa Sollievo della Sofferenza” in San Giovanni Rotondo (Gargano, Center East Coast of Italy) from 2001 to 2008, as recently described [29,30]. All patients had either a stenosis >50% in at least one coronary major vessel at coronary angiography or a previous MI. Follow-up information on outcomes was collected yearly from 2002 to 2011. The only exclusion criterion was the presence of poor life expectancy for non diabetes-related diseases. The end-point was here CV mortality. Confirmation of the event was obtained from death certificates (i.e. according to the international classification of diseases’ codes: 428.1- ninth edition - and I21.0-I21.9, I25.9, I46.9-I50.9, I63.0, I63.9, I70.2- tenth edition).

Clinical data at baseline were obtained from a standardized interview and examination. Smoking habits and history of hypertension, dyslipidemia and MI as well as glucose-lowering treatment were also recorded at time of examination. Data regarding medications were confirmed by review of medical records. Serum total and high-molecular weight (HMW) adiponectin were measured in 359 (98%) participants.

The study was approved by the Institutional Ethic Committee IRCCS “Casa Sollievo della Sofferenza”, San Giovanni Rotondo.

#### *Health Professional Follow-up Study (HPFS) and Nurses’ Health Study (NHS)*

The HPFS is a prospective cohort study of 51,529 US male health professionals who were 40 – 75 years old at study inception in 1986 [31]. Between 1993 and 1999, 18,159 men provided blood samples. The NHS is a prospective cohort study of 121,700 female registered nurses

who were 30 – 55 years old at study inception in 1976 when all of them completed a mailed questionnaire on their medical history and lifestyle [32]. A total of 32,826 women provided blood samples between 1989 and 1990.

In both cohorts, information about health and disease has been collected at baseline and biennially by self-administered questionnaires since inception and renal function was estimated by the simplified MDRD equation [33]. Study individuals in the present analysis from both NHS and HPFS were all patients with type 2 diabetes who provided blood samples, during 1993 and 1994 for HPFS and during 1989 and 1990 for NHS, respectively. We followed these subjects and documented incident CV disease and related death after blood draw. Diabetes cases were defined as self-reported diabetes at baseline confirmed by a validated supplementary questionnaire. For study individuals recruited before the release of the American Diabetes Association criteria in 1997, the National Diabetes Data Group criteria were used to define diabetes [34]. The validity of this method has been confirmed [35]. The American Diabetes Association diagnostic criteria were used for diabetes diagnosis from 1998 onwards [36].

CV deaths were confirmed by review of medical records or autopsy reports with the permission of the next of kin [37].

In the current prospective analysis of plasma total adiponectin levels and CV mortality risk, where follow-up began at the time of blood collection, participants with established CV disease (defined as the occurrence of MI or coronary artery bypass grafting or stroke) before the diagnosis of diabetes were excluded from the present analyses [38,39]. Eight hundred and thirty three diabetic men (146 CV deaths during 14-year follow-up) and 902 diabetic women (144 CV deaths during 20-year follow-up) were included.

The study was approved by the Human Research Committee at the Brigham and Women’s Hospital, Boston, MA, USA, and all participants provided written informed consent.

#### **Sample collection and measurement of circulating total and HMW adiponectin levels**

In the GHS-prospective designs blood samples were collected between 8:00 and 9:00 AM after an overnight fast.

In the NHS and HPFS, blood samples were collected in EDTA blood tubes in the men and heparin blood tubes in the women, chilled, and sent back by prepaid overnight courier. Once in the laboratory, the samples were centrifuged and aliquoted into cryotubes as plasma, buffy coat, and red blood cells. Cryotubes were then stored in liquid nitrogen freezers at –130°C or lower [40].

In the GHS-prospective design, serum total and HMW adiponectin concentrations were measured by

ELISA (Alpco, Salem, NH) as previously described [41]. The intra-assay coefficients of variation were 5.4 and 4.9, and 5.0 and 4.8% for total adiponectin and HMW adiponectin, respectively.

In the NHS and HPFS, plasma total adiponectin was measured separately, in two different laboratories, by competitive radioimmunoassay (Linco Research, St. Charles, MO). A similar coefficient of variation ranging 3-4%, was observed in both cohorts [42].

### Statistical methods

Patients' baseline characteristics were reported as mean  $\pm$  standard deviation (SD), median (range) and percentages for continuous and categorical variables, respectively.

In all prospective studies, the time variable was defined as the time between the baseline examination and date of the event (CV mortality), or, for subjects who did not experience the event, the date of the last available clinical follow-up. Incidence rates for CV mortality were expressed as the number of events per total number of person-years (py). Univariate and multivariate (taking into account several covariates as described in Results) Cox proportional hazards regression analyses were performed to assess the association between adiponectin values and the event occurrence. Risks were reported as Hazard Ratios (HR) along with 95% CI per SD increase in adiponectin levels and for tertiles of its distribution. The same analyses were carried out in males and females from the GHS-prospective design, separately.

Linearity of association was tested comparing, in terms of AIC (Akaike Information Criterion), a linear and a quadratic model.

As a sensitivity analysis, we performed a competing risks analysis, where the non CV death is the competitor of CV death, using subdistribution hazard ratios estimated through Fine and Gray proportional hazards regression [43].

Meta-analysis of pooled estimates was obtained using the fixed effects meta-analysis model. Between-study heterogeneity was assessed using the Cochran Q test.

In the pooled analysis we had 80% power to detect an HR of 1.25 for 1 SD adiponectin with a Type I Error (alpha) of 0.05 both in men and in women.

A p-value  $<0.05$  was considered as significant. All analyses were performed using SAS Release 9.1.3 (SAS Institute, Cary, NC, USA) and R software (package "cmprsk").

## Results

### The GHS-prospective design

Baseline clinical features of study participants are summarized in Table 1. During follow-up ( $5.4 \pm 2.5$  years), 58 CV deaths occurred, corresponding to an overall annual incidence rate of 3.0% (58 events/1,934 py). Median serum total adiponectin was 4.4 (range: 0.97-21.8)  $\mu\text{g/ml}$ . Each SD increment of serum adiponectin was associated

with a 30% increase in the risk of CV mortality (HR = 1.30, 95% CI: 1.09-1.56,  $p = 0.005$ ). The linearity of this association was confirmed by comparing AICs (linear: 632.6 vs. quadratic: 633.5).

This association was independent of baseline clinical features including age, sex, smoking habits, BMI, HbA1c, anti-diabetic therapy, hypertension, total cholesterol, HDL cholesterol, triglycerides and hsCRP (adiponectin SD HR = 1.44, 95% CI: 1.14-1.82;  $p = 0.002$ ). Duration of diabetes was not included in this model because collinear with age at recruitment.

In contrast, no association was observed with non CV death (23 events; HR = 1.07, 95% CI: 0.73-1.55;  $p = 0.74$ ); this makes very likely that the association we observed with all-cause mortality (81 events; HR = 1.24, 95% CI: 1.05-1.46;  $p = 0.01$ ) is mainly driven by that with CV mortality.

Finally, competing risks analysis, in which non CV death was used as competing risk, provided further support to the association between serum adiponectin and CV mortality (HR = 1.24, 95% CI: 1.08-1.43,  $p = 0.003$ ).

According to our predefined aim, data were then analyzed in men and women, separately. Median (range) total adiponectin were 4.2 (0.97-21.8) and 5.0 (0.67-19.2), in men and women, respectively. The association with CV mortality was clearly evident and statistically significant among men (adiponectin SD HR = 1.41, 95% CI: 1.16-1.70), but not women (adiponectin SD HR = 1.02, 95% CI: 0.63-1.62) (Table 2), thus suggesting differences across sex ( $p$  for HR heterogeneity 0.09). The linearity of the association was confirmed by comparing AICs (linear: 417.0 vs. quadratic: 417.8). This association did not significantly change in the adjusted model (Table 2).

When men were stratified according to tertiles of adiponectin levels a trend toward an increased risk of CV mortality from tertile 1 (i.e. the lowest values) to tertile 3 (i.e. the highest values) was observed (adjusted  $p$  for trend = 0.026) (Figure 1).

Very similar associations both in the whole sample as well as in men and women analyzed separately were obtained for HMW adiponectin (see Additional file 1: Table S1).

### The HPFS

The baseline clinical features of study participants, including by study design, only male patients, are summarized in Table 1. During an average 14 years (1994-2008) of follow-up since blood samples were obtained, 146 CV deaths occurred in 10,024 py, corresponding to an overall annual incidence rate of 2.8%. Median plasma total adiponectin was 14.07 (range: 1.41-63.78)  $\mu\text{g/ml}$ . Mirroring the results obtained among men from the GHS-prospective design, plasma adiponectin levels were associated with CV mortality (adiponectin SD HR = 1.26,

**Table 1 Baseline clinical characteristics of participants from GHS-prospective design, NHS and HPFS cohorts**

|                                | GHS-prospective design |                       | HPFS                  | NHS                   |
|--------------------------------|------------------------|-----------------------|-----------------------|-----------------------|
|                                | Men (n = 242)          | Women (n = 117)       | Men (n = 833)         | Women (n = 902)       |
| Age (years)                    | 63.6 ± 8.3             | 66.1 ± 7.5            | 63.6 ± 8.6            | 59.1 ± 7.2            |
| Current Smokers (%)            | 55 (22.7)              | 9 (7.7)               | 56 (6.7)              | 123 (13.6)            |
| Diabetes duration (years)      | 12.9 ± 8.8             | 15.7 ± 9.8            | 7.8 ± 9.6             | 11.0 ± 9.3            |
| BMI (kg/m <sup>2</sup> )       | 29.4 ± 4.3             | 31.8 ± 5.4            | 27.8 ± 4.6            | 29.7 ± 6.3            |
| HbA <sub>1c</sub> % (mmol/mol) | 8.6 ± 1.9 (70 ± 20.8)  | 8.7 ± 1.8 (72 ± 19.7) | 7.3 ± 1.5 (56 ± 16.4) | 7.1 ± 1.8 (54 ± 19.7) |
| Total cholesterol (mg/dl)      | 175.4 ± 46.0           | 176.7 ± 45.3          | 209.6 ± 40.4          | 229.6 ± 45.4          |
| HDL-cholesterol (mg/dL)        | 42.2 ± 14.2            | 46.4 ± 15.0           | 40.2 ± 11.1           | 51.7 ± 15.9           |
| Triglycerides (mg/dL)          | 158.5 ± 98.8           | 140.3 ± 74.3          | 191.0 ± 101.7         | 208.9 ± 152.4         |
| hsCRP (mg/L)                   | 6.7 ± 14.3             | 4.9 ± 8.3             | 3.2 ± 5.4             | 7.9 ± 8.8             |
| Anti-diabetic therapy (%)      | 126 (52.0)             | 68 (58.1)             | 603 (72.4)            | 493 (54.7)            |
| Hypertension (%)               | 198 (81.8)             | 107 (91.5)            | 393 (47.2)            | 599 (66.4)            |

Continuous variables were reported as mean ± SD whereas categorical variables as total frequency and percentages.

GHS: Gargano Heart Study; HPFS: Health Professional Follow-up Study; NHS, Nurses' Health Study.

BMI: body mass index; HbA<sub>1c</sub>: glycated haemoglobin A<sub>1c</sub>, hsCRP: high sensitivity C-reactive protein.

95% CI: 1.10-1.45) (Table 2). The linearity of this association was confirmed by comparing AICs (linear: 1583 vs. quadratic: 1590). This association did not significantly change in the adjusted model (Table 2).

Further adjustments for alcohol consumption and eGFR values (which were not available in the GHS) did not change the observed association (adiponectin SD HR = 1.46, 95% CI: 1.24-1.72).

Also in this case tertiles stratification according to adiponectin levels, revealed a trend toward an increased CV mortality rate (adjusted p for trend <0.0001) (Figure 1).

### The NHS

Baseline clinical features of study participants, including by study design, only female patients, are summarized in Table 1. During an average 20-year follow-up (1990–2010), 144 CV deaths occurred 15,074 py, corresponding

to an overall annual incidence rate of 1.9%. Median plasma adiponectin was 5.88 (range: 0.80-42.07) µg/ml. Mirroring the results obtained among women from the GHS-prospective design, total plasma adiponectin was not associated with CV mortality (HR = 0.91, 95% CI: 0.75-1.09) (Table 2). This association did not significantly change in the adjusted model (Table 2). Similar results were obtained after further adjustment for alcohol consumption and renal function (HR = 1.05, 95% CI: 0.85-1.31).

### Pooled analysis

In a pooled analysis, the association between circulating adiponectin and CV mortality was strongly evident among men (adjusted HR = 1.47, 95% CI 1.27-1.70, p = 2 × 10<sup>-7</sup>), but not among women (adjusted HR = 1.07, 95% CI 0.86-1.33, p = 0.53) Table 2. The difference between HRs

**Table 2 Risk of cardiovascular mortality by 1 SD of circulating adiponectin levels**

| Study samples       | Number of participants/events | Model 1          |                    | Model 2           |                    |
|---------------------|-------------------------------|------------------|--------------------|-------------------|--------------------|
|                     |                               | HR (95% CI)      | p value            | HR (95% CI)       | p value            |
| Men                 |                               |                  |                    |                   |                    |
| GHS                 | 242/42                        | 1.41 (1.16-1.70) | 5×10 <sup>−4</sup> | 1.54 (1.19-2.01)  | 1×10 <sup>−3</sup> |
| HPFS                | 833/146                       | 1.26 (1.10-1.45) | 1×10 <sup>−3</sup> | 1.44 (1.21-1.72)  | 1×10 <sup>−4</sup> |
| POOLED <sup>§</sup> | 1075/188                      | 1.31 (1.17-1.47) | 2×10 <sup>−6</sup> | 1.47 (1.27-1.70)* | 2×10 <sup>−7</sup> |
| Women               |                               |                  |                    |                   |                    |
| GHS                 | 117/16                        | 1.02 (0.63-1.62) | 0.82               | 0.98 (0.48-2.01)  | 0.96               |
| NHS                 | 902/144                       | 0.91 (0.75-1.09) | 0.31               | 1.08 (0.86-1.35)  | 0.49               |
| POOLED <sup>§</sup> | 1019/160                      | 0.92 (0.78-1.10) | 0.37               | 1.07 (0.86-1.33)  | 0.53               |

GHS, Gargano Heart Study; HPFS, Health Professional Follow-up Study; NHS, Nurses' Health Study.


Model 1: unadjusted.

Model 2: adjusted for age, sex, smoking habit, BMI, HbA<sub>1c</sub>, anti-diabetic therapy, hypertension, total cholesterol, HDL cholesterol, triglycerides and hsCRP.

<sup>§</sup>pooled analyses were adjusted for "study sample".

\*p = 0.018 vs. model 2, pooled HR in women.





**Figure 1** Hazard ratios (95% CI) of CV mortality in men from the GHS-prospective design and HPFS, according to baseline tertile of circulating adiponectin levels (T1-T3, range in parentheses). Hazard ratios were estimated by Cox regression after adjusting for age, sex, smoking habits, BMI, HbA1c, anti-diabetic therapy, hypertension, total cholesterol, HDL cholesterol, triglycerides and hsCRP.

obtained in men and women was statistically significant ( $p$  for heterogeneity = 0.018).

## Discussion

In this study we investigated in three different cohorts the association of circulating adiponectin on CV mortality in men and women with type 2 diabetes. To the best of our knowledge, this is the first report showing that i) adiponectin is positively related to CV mortality in type 2 diabetes and ii) a sexual dimorphism influences such paradoxical association, which is observable only in men.

Despite the direct association between serum adiponectin and CV mortality is difficult to reconcile with the well-recognized role of adiponectin as an anti-inflammatory, anti-atherogenic and insulin sensitizer factor [2,3] and with the previously reported association with reduced risk of CHD [6,7,27], the same counter intuitive finding has been recently described in individuals from the general population and several selected clinical setting [11-17,19-23]. In addition, high adiponectin levels have been reported to predict all-cause mortality in the general population and in patients with CV disease [18-21], as well as in elderly people with type 2 diabetes [44].

Taken together our present and all previous studies strongly point to a paradoxical association of serum adiponectin on mortality rate.

The biology underlying such unexpected association is unknown and cannot be unraveled by observational studies. One can here only speculate that, in our study, increased adiponectin may be interpreted as a marker of a tentative, though not sufficient, homeostatic mechanism in individuals who are at high CV risk [45]. Conversely, it is also possible that in some individuals, serum adiponectin is increased because of adiponectin resistance, which, in turn, does have the potential of playing a direct pathogenic role in increasing risk of CV mortality [3,46,47]. It is also possible that increased adiponectin levels is a

consequence of increased N-terminal pro brain natriuretic peptide (NT-proBNP) [18], an established marker of CV disease.

The second important finding of our study is the sex-specific association between circulating adiponectin and CV mortality with the deleterious role of high adiponectin levels being observable only among men. Controversial findings have been so far reported as far as a sexually dimorphic association of adiponectin with metabolic and atherosclerosis-related clinical events is concerned. In fact, while no sex-specific association has been described on CHD in the general population [27] and on CV events in a very small sample of patients with type 2 diabetes [28], high adiponectin levels do predict progressive kidney dysfunction among men, but not women, in individuals with chronic kidney disease [25].

Whether the sex specific associations of adiponectin on metabolic and atherosclerosis-related events we and others [24,25] observed is due to the interaction between circulating adiponectin and either sex-linked genes and/or sexual hormone effects is not known and deserves further investigations. Sex-specific associations have been reported also for other CV risk factors, including those between elevated plasma levels of sTNF-receptors and coronary heart disease [48], between uric acid and atrial fibrillation [49] and between prolactin and cardiac remodeling [50]. A better understanding of the different role of adiponectin on CV disease across sexes, might be gained by verifying whether adiponectin changes, as obtained by interventional studies, are differently related to CV outcomes in males and females.

We acknowledge that the statistical level of sex-specific association indicate the need of caution in interpreting our results. Nonetheless, while waiting for further studies in additional samples, present and previous findings [24,25], definitively suggest the need of taking into account possible sex-specific associations when addressing the role of CV risk factors; in addition, they point to the

need of setting up studies specifically designed to unravel the different biology underlying CV risk in men and women.

Our study has some strength as follows. We utilized well-established prospectively analyzed cohorts with a completeness of information, including standardized clinical evaluations and hard end-points validated by medical records or death certificates. In addition, in the GHS-prospective design, very similar data were obtained with HMW-adiponectin, the biological active form of circulating adiponectin, thus reinforcing data obtained by measuring total adiponectin levels. Most importantly, the sex-specific association of adiponectin on CV death, which has been validated in independent samples, is entirely novel and plays the important function of reinforcing the belief that a different biology underlies CV risk in men and women [51]. Finally, since our results were very similar in individuals from both Italy and the US, it is very likely that they can be generalized to all diabetic patients of European ancestry, no matter where they live and the environment they are exposed to. In this context, it is of note that several clinical features, including HbA1c, the proportion of hypertension, and - as far as males from HPFS are concerned - a relatively low proportion of smokers -, were quite heterogeneous across study populations.

A major limitation of our investigation is intrinsic to its very nature. As an observational study, it cannot address mechanistic explanations of the association we observed, with only hypothesis being offered.

In addition, it remains unknown whether the paradoxical association between serum adiponectin and CV mortality we observed in men of European ancestry is a general phenomenon also observable in individuals of different ancestries. Also, given that adiponectin measurement was carried out in different specimens (i.e. serum or plasma) by three different laboratories using different assays, a direct comparison of absolute values across the different study samples cannot be done. Finally, the role of potential bias affecting adiponectin levels, including polypharmacy, diabetic kidney disease and other residual or unmeasured confounding factors not taken into account in our study cannot be excluded, thus inviting for caution in interpreting our results.

In conclusion, to the best of our knowledge this is the first study reporting that, quite unexpectedly given its beneficial role in atherosclerotic processes [2,3], high circulating adiponectin predicts increased CV mortality in patients with type 2 diabetes. It is of note that such association was only observed in diabetic men, whereas no association at all was detected in diabetic women. Further studies aimed at unraveling the mechanisms through which adiponectin influences CV mortality and how this occurs in a sex-specific manner are certainly required.

The composite, not straightforward, scenario drawn by our findings points to the general need of characterizing in deep details the role of novel and promising markers of CV disease before to upgrade them at the level of usable tools in the clinical set.

## Additional file

**Additional file 1: Table S1.** HR (95% CI) of cardiovascular mortality by 1 SD of serum HMW adiponectin levels in the GHS-prospective design.

## Competing interests

The authors declare that they have no competing interests.

## Authors' contributions

CM, MX, SB, FBH, LQ and VT participated in study concept and design, acquisition of data, and interpretation of results. CM, MX and MC participated in statistical analysis. LS, CDB, GP, TH, YZ, YL and GF performed laboratory testing, acquired laboratory and clinical data used in the study. CM, MX, LQ and VT obtained funding, drafted the article and all authors participated in critical revision and approved the final version of the manuscript. CM and VT are the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data. All authors read and approved the final manuscript.

## Authors' information

Lu Qi and Vincenzo Trischitta shared the responsibility to oversee the entire study.

## Acknowledgements

We are indebted to the staffs and participants of the GHS, HPFS and NHS for their dedication and contributions.

This study was supported by Accordo Programma Quadro in Materia di Ricerca Scientifica nella Regione Puglia-PST 2006 and PO Puglia FESR 2007-2013, Italian Ministry of Health grants RC2011, RC2012, RC2013, RC2014, EFSD/Pfizer grant and SID-FO.DI.RI (CM) and by grant No. 81270877 from the National Natural Science Foundation of China (MX). Dr Qi was supported by grants from the National Heart, Lung, and Blood Institute (HL071981), the National Institute of Diabetes and Digestive and Kidney Diseases (DK091718), the Boston Obesity Nutrition Research Center (DK46200), and United States - Israel Binational Science Foundation Grant2011036. Dr Qi was a recipient of the American Heart Association Scientist Development Award (0730094 N).

## Author details

<sup>1</sup>Research Unit of Diabetes and Endocrine Diseases IRCCS Casa Sollievo della Sofferenza, Viale Padre Pio, 71013 San Giovanni Rotondo, Italy. <sup>2</sup>Department of Nutrition, Harvard School of Public Health, Boston, MA, USA. <sup>3</sup>Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Department of Endocrine and Metabolic Diseases, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. <sup>4</sup>Unit of Biostatistics IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy. <sup>5</sup>Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Channing Division of Network Medicine, Boston, MA, USA. <sup>6</sup>Unit of Endocrinology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy. <sup>7</sup>Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.

Received: 16 July 2014 Accepted: 22 August 2014

## References

1. Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njølstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J: **Diabetes mellitus, fasting glucose, and risk of cause-specific death.** *N Engl J Med* 2011, **364**(9):829-841.

2. Kadowaki T, Yamauchi T: **Adiponectin and adiponectin receptors.** *Endocr Rev* 2005, **26**(3):439–451.
3. Turer AT, Scherer PE: **Adiponectin: mechanistic insights and clinical implications.** *Diabetologia* 2012, **55**(9):2319–2326.
4. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB: **Plasma adiponectin levels and risk of myocardial infarction in men.** *JAMA* 2004, **291**(14):1730–1737.
5. Persson J, Lindberg K, Gustafsson TP, Eriksson P, Paulsson-Berne G, Lundman P: **Low plasma adiponectin concentration is associated with myocardial infarction in young individuals.** *J Intern Med* 2010, **268**(2):194–205.
6. Sattar N, Wannamethee G, Sarwar N, Tchernova J, Cherry L, Wallace AM, Danesh J, Whincup PH: **Adiponectin and coronary heart disease: a prospective study and meta-analysis.** *Circulation* 2006, **114**(7):623–629.
7. Pischon T, Hu FB, Girman CJ, Rifai N, Manson JE, Rexrode KM, Rimm EB: **Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in women.** *Atherosclerosis* 2011, **219**(1):322–329.
8. Kim JY, Choi EY, Mun HS, Min PK, Yoon YW, Lee BK, Hong BK, Rim SJ, Kwon HM: **Usefulness of metabolic syndrome score in the prediction of angiographic coronary artery disease severity according to the presence of diabetes mellitus: relation with inflammatory markers and adipokines.** *Cardiovasc Diabetol* 2013, **12**:140.
9. Karas MG, Benkeser D, Arnold AM, Bartz TM, Djousse L, Mukamal KJ, Ix JH, Ziemann SJ, Siscovick DS, Tracy RP, Mantzoros CS, Gottdiener JS, De Filippi CR, Kizer JR: **Relations of plasma total and high-molecular-weight adiponectin to new-onset heart failure in adults  $\geq 65$  years of age (from the Cardiovascular Health study).** *Am J Cardiol* 2014, **113**(2):328–334.
10. Baldasseroni S, Antenore A, Di Serio C, Orso F, Lonetto G, Bartoli N, Foschini A, Marella A, Pratesi A, Scarantino S, Fumagalli S, Monami M, Mannucci E, Marchionni N, Tarantini F: **Adiponectin, diabetes and ischemic heart failure: a challenging relationship.** *Cardiovasc Diabetol* 2012, **11**:151.
11. Dekker JM, Funahashi T, Nijpels G, Pilz S, Stehouwer CD, Snijder MB, Bouter LM, Matsuzawa Y, Shimomura I, Heine RJ: **Prognostic value of adiponectin for cardiovascular disease and mortality.** *J Clin Endocrinol Metab* 2008, **93**(4):1489–1496.
12. Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Clark LT, Pinsky DJ, Marmur JD: **Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain.** *Eur Heart J* 2006, **27**(19):2300–2309.
13. Pilz S, Mangge H, Wellnitz B, Seelhorst U, Winkelmann BR, Tiran B, Boehm BO, März W: **Adiponectin and mortality in patients undergoing coronary angiography.** *J Clin Endocrinol Metab* 2006, **91**(11):4277–4286.
14. Poehls J, Wassel CL, Harris TB, Havel PJ, Swarbrick MM, Cummings SR, Newman AB, Satterfield S, Kanaya AM, Study HA: **Association of adiponectin with mortality in older adults: the health, aging, and body composition study.** *Diabetologia* 2009, **52**(4):591–595.
15. Wannamethee SG, Whincup PH, Lennon L, Sattar N: **Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure.** *Arch Intern Med* 2007, **167**(14):1510–1517.
16. Lindberg S, Pedersen SH, Møgelvang R, Bjerre M, Frydystk J, Flyvbjerg A, Galatius S, Jensen JS: **Usefulness of adiponectin as a predictor of all cause mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.** *Am J Cardiol* 2012, **109**(4):492–496.
17. Kizer JR, Benkeser D, Arnold AM, Mukamal KJ, Ix JH, Ziemann SJ, Siscovick DS, Tracy RP, Mantzoros CS, Defilippi CR, Newman AB, Djousse L: **Associations of total and high-molecular-weight adiponectin with all-cause and cardiovascular mortality in older persons: the cardiovascular health study.** *Circulation* 2012, **126**(25):2951–2961.
18. Wannamethee SG, Welsh P, Whincup PH, Sawar N, Thomas MC, Gudnason V, Sattar N: **High adiponectin and increased risk of cardiovascular disease and mortality in asymptomatic older men: does NT-proBNP help to explain this association?** *Eur J Cardiovasc Prev Rehabil* 2011, **18**(1):65–71.
19. Persson J, Folkersen L, Ekstrand J, Helleberg J, Gabrielsen A, Lundman P, Hedin U, Paulsson-Berne G: **High plasma adiponectin concentration is associated with all-cause mortality in patients with carotid atherosclerosis.** *Atherosclerosis* 2012, **225**(2):491–496.
20. Sook Lee E, Park SS, Kim E, Sook Yoon Y, Ahn HY, Park CY, Ho Yun Y, Woo Oh S: **Association between adiponectin levels and coronary heart disease and mortality: a systematic review and meta-analysis.** *Int J Epidemiol* 2013, **42**(4):1029–1039.
21. Wu ZJ, Cheng YJ, Gu WJ, Aung LH: **Adiponectin is associated with increased mortality in patients with already established cardiovascular disease: a systematic review and meta-analysis.** *Metabolism* 2014, **63**(9):1157–1166.
22. Forsblom C, Thomas MC, Moran J, Saraheimo M, Thorn L, Wadén J, Gordin D, Frydystk J, Flyvbjerg A, Groop PH, FinnDiane Study Group: **Serum adiponectin concentration is a positive predictor of all-cause and cardiovascular mortality in type 1 diabetes.** *J Intern Med* 2011, **270**(4):346–355.
23. Alam A, Molnar MZ, Czira ME, Rudas A, Ujszaszi A, Kalantar-Zadeh K, Rosivall L, Mucsi I: **Serum adiponectin levels and mortality after kidney transplantation.** *Clin J Am Soc Nephrol* 2013, **8**(3):460–467.
24. Tabák AG, Carstensen M, Witte DR, Brunner EJ, Shipley MJ, Jokela M, Roden M, Kivimäki M, Herder C: **Adiponectin trajectories before type 2 diabetes diagnosis: Whitehall II study.** *Diabetes Care* 2012, **35**(12):2540–2547.
25. Kollerits B, Fliser D, Heid IM, Ritz E, Kronenberg F, Group MS: **Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the mild to moderate kidney disease study.** *Kidney Int* 2007, **71**(12):1279–1286.
26. Durand JL, Nawrocki AR, Scherer PE, Jelicks LA: **Gender differences in adiponectin modulation of cardiac deficiency in mice deficient in endothelial nitric oxide synthase.** *J Cell Biochem* 2012, **113**(10):3276–3287.
27. Côté M, Cartier A, Reuwer AQ, Arsenault BJ, Lemieux I, Després JP, Wareham NJ, Kastelein JJ, Boekholdt SM, Khaw KT: **Adiponectin and risk of coronary heart disease in apparently healthy men and women (from the EPIC-Norfolk prospective population study).** *Am J Cardiol* 2011, **108**(3):367–373.
28. Krzyzanowska K, Aso Y, Mittermayer F, Inukai T, Brix J, Scherthaner G: **High-molecular-weight adiponectin does not predict cardiovascular events in patients with type 2 diabetes.** *Transl Res* 2009, **153**(4):199–203.
29. Bacci S, Rizza S, Prudente S, Spoto B, Powers C, Facciorusso A, Pacilli A, Lauro D, Testa A, Zhang YY, Di Stolfo G, Mallamaci F, Tripepi G, Xu R, Mangiacotti D, Aucella F, Lauro R, Gervino EV, Hauser TH, Copetti M, De Cosmo S, Pellegrini F, Zoccali C, Federici M, Doria A, Trischitta V: **The ENPP1 Q121 variant predicts major cardiovascular events in high-risk individuals: evidence for interaction with obesity in diabetic patients.** *Diabetes* 2011, **60**(3):1000–1007.
30. Menzaghi C, Bacci S, Salvemini L, Mendonca C, Palladino G, Fontana A, De Bonis C, Marucci A, Goheen E, Prudente S, Morini E, Rizza S, Kanagaki A, Fini G, Mangiacotti D, Federici M, De Cosmo S, Pellegrini F, Doria A, Trischitta V: **Serum resistin, cardiovascular disease and all-cause mortality in patients with type 2 diabetes.** *PLoS One* 2013, **8**(6):e64729.
31. Rimm EB, Giovannucci EL, Willett WC, Colditz WC, Ascherio A, Rosner B, Stampfer MJ: **Prospective study of alcohol consumption and risk of coronary disease in men.** *Lancet* 1991, **338**(8765):464–468.
32. Colditz GA, Manson JE, Hankinson SE: **The nurses' health study: 20-year contribution to the understanding of health among women.** *J Womens Health* 1997, **6**(1):49–62.
33. Lin J, Hu FB, Qi L, Curhan GC: **Genetic polymorphisms of angiotensin-2 type 1 receptor and angiotensinogen and risk of renal dysfunction and coronary heart disease in type 2 diabetes mellitus.** *BMC Nephrol* 2009, **10**:9.
34. National Diabetes Data Group: **Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.** *Diabetes* 1979, **28**(12):1039–1057.
35. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Krolewski AS, Rosner B, Arky RA, Speizer FE, Hennekens CH: **A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women.** *Arch Intern Med* 1991, **151**(6):1141–1147.
36. Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care* 1997, **20**(7):1183–1197.
37. Zhang WL, Lopez-Garcia E, Li TY, Hu FB, Van Dam RM: **Coffee consumption and risk of cardiovascular events and all-cause mortality among women with type 2 diabetes.** *Diabetologia* 2009, **52**(5):810–817.
38. Qi L, Li T, Rimm E, Zhang C, Rifai N, Hunter D, Doria A, Hu FB: **The +276 polymorphism of the APM1 gene, plasma adiponectin concentration, and cardiovascular risk in diabetic men.** *Diabetes* 2005, **54**(5):1607–1610.
39. Qi L, Doria A, Manson JE, Meigs JB, Hunter D, Mantzoros CS, Hu FB: **Adiponectin genetic variability, plasma adiponectin, and cardiovascular risk in patients with type 2 diabetes.** *Diabetes* 2006, **55**(5):1512–1516.
40. Qi Q, Workalemahu T, Zhang C, Hu FB, Qi L: **Genetic variants, plasma lipoprotein (a) levels, and risk of cardiovascular morbidity and mortality**



- among two prospective cohorts of type 2 diabetes. *Eur Heart J* 2012, **33**(3):325–334.
41. Menzaghi C, Salvemini L, Paroni G, De Bonis C, Mangiacotti D, Fini G, Doria A, Di Paola R, Trischitta V: **Circulating high molecular weight adiponectin isoform is heritable and shares a common genetic background with insulin resistance in nondiabetic White Caucasians from Italy: evidence from a family-based study.** *J Intern Med* 2009, **267**(3):287–294.
  42. Pischon T, Hotamisligil GS, Rimm EB: **Adiponectin: stability in plasma over 36 hours and within-person variation over 1 year.** *Clin Chem* 2003, **49**(4):650–652.
  43. Fine JP, Gray RJ: **A proportional hazard model for the subdistribution of a competing risk.** *J Am Stat Assoc* 1999, **94**:496–509.
  44. Singer JR, Palmas W, Teresi J, Weinstock R, Shea S, Luchsinger JA: **Adiponectin and all-cause mortality in elderly people with type 2 diabetes.** *Diabetes Care* 2012, **35**(9):1858–1863.
  45. Sattar N, Nelson SM: **Adiponectin, diabetes, and coronary heart disease in older persons: unraveling the paradox.** *J Clin Endocrinol Metab* 2008, **93**(9):3299–3301.
  46. Khan RS, Kato TS, Chokshi A, Chew M, Yu S, Wu C, Singh P, Cheema FH, Takayama H, Harris C, Reyes-Soffer G, Knöll R, Milting H, Naka Y, Mancini D, Schulze PC: **Adipose tissue inflammation and adiponectin resistance in patients with advanced heart failure: correction after ventricular assist device implantation.** *Circ Heart Fail* 2012, **5**(3):340–348.
  47. Van Berendoncks AM, Garnier A, Beckers P, Hoymans VY, Possemiers N, Fortin D, Martinet W, Van Hoof V, Vrints CJ, Ventura-Clapier R, Conraads VM: **Functional adiponectin resistance at the level of the skeletal muscle in mild to moderate chronic heart failure.** *Circ Heart Fail* 2010, **3**(2):185–194.
  48. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshupura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB: **Inflammatory markers and the risk of coronary heart disease in men and women.** *N Engl J Med* 2004, **351**(25):2599–2610.
  49. Suzuki S, Sagara K, Otsuka T, Matsuno S, Funada R, Uejima T, Oikawa Y, Koike A, Nagashima K, Kirigaya H, Yajima J, Sawada H, Aizawa T, Yamashita T: **Gender-specific relationship between serum uric acid level and atrial fibrillation prevalence.** *Circ J* 2012, **76**(3):607–611.
  50. Haring R, Völzke H, Vasan RS, Felix SB, Nauck M, Dörr M, Wallaschofski H: **Sex-specific associations of serum prolactin concentrations with cardiac remodeling: longitudinal results from the Study of Health Pomerania (SHIP).** *Atherosclerosis* 2012, **221**(2):570–576.
  51. Kanaya AM, Grady D, Barrett-Connor E: **Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: a meta-analysis.** *Arch Intern Med* 2002, **162**(15):1737–1745.

doi:10.1186/s12933-014-0130-y

**Cite this article as:** Menzaghi et al.: Circulating adiponectin and cardiovascular mortality in patients with type 2 diabetes mellitus: evidence of sexual dimorphism. *Cardiovascular Diabetology* 2014 **13**:130.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

